Windtree Therapeutics Inc
NASDAQ:WINT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Toa Oil Co Ltd
TSE:5008
|
JP |
|
Truscreen Group Ltd
NZX:TRU
|
NZ |
|
H
|
H P Cotton Textile Mills Ltd
BSE:502873
|
IN |
|
Shreyans Industries Ltd
NSE:SHREYANIND
|
IN |
|
Chemcon Speciality Chemicals Ltd
NSE:CHEMCON
|
IN |
|
T
|
Tanco Holdings Bhd
KLSE:TANCO
|
MY |
|
ITI Ltd
NSE:ITI
|
IN |
|
N
|
Nichireki Co Ltd
TSE:5011
|
JP |
|
B
|
Bright Oceans Inter-Telecom Corp
SSE:600289
|
CN |
|
N
|
Net Lease Office Properties
NYSE:NLOP
|
US |
|
A
|
Anhui Guangxin Agrochemical Co Ltd
SSE:603599
|
CN |
|
P
|
Pihlajalinna Oyj
OMXH:PIHLIS
|
FI |
|
N1 Holdings Ltd
ASX:N1H
|
AU |
|
HELLA GmbH & Co KGaA
XETRA:HLE
|
DE |
|
Axiscades Technologies Ltd
NSE:AXISCADES
|
IN |
|
BEST Inc
NYSE:BEST
|
CN |
Windtree Therapeutics Inc
Other
Windtree Therapeutics Inc
Other Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Windtree Therapeutics Inc
NASDAQ:WINT
|
Other
-$168k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other
$45m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other
-$440m
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
20%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other
-$10.9B
|
CAGR 3-Years
-372%
|
CAGR 5-Years
-161%
|
CAGR 10-Years
-34%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other
-$366.2m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other
-$542.4m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-5%
|
|
Windtree Therapeutics Inc
Glance View
Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical and medical device company, which engages in the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. The company is headquartered in Warrington, Pennsylvania and currently employs 33 full-time employees. The Company’s development programs are primarily focused on the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. Its Cardiovascular Program’s products candidates include Istaroxime, Oral SERCA2a Activators and Rostafuroxin. Its Pulmonary Program’s product candidates include Lyophilized KL4 Surfactant and AEROSURF (aerosolized KL4 surfactant based on ADS technology). The Company’s lead product candidate, istaroxime, is a dual-acting agent being developed to improve cardiac function in patients with acute heart failure (AHF) with a potentially differentiated safety profile from existing treatments. Istaroxime demonstrated significant improvement in both diastolic and systolic aspects of cardiac function and is under phase II clinical trials.
See Also
What is Windtree Therapeutics Inc's Other?
Other
-168k
USD
Based on the financial report for Mar 31, 2025, Windtree Therapeutics Inc's Other amounts to -168k USD.
What is Windtree Therapeutics Inc's Other growth rate?
Other CAGR 1Y
-68%
Over the last year, the Other growth was -68%.
